Crisis shows companies need social licence to operate, Federated Hermes says

spike

FILE PHOTO: A view of a nearly deserted Broad street and the New York Stock Exchange building in the financial district of lower Manhattan during the outbreak of the coronavirus disease (COVID-19) in New York City, New York, U.S., April 3, 2020. REUTERS/Mike Segar

LONDON (Reuters) – Federated Hermes (FHI.N) has written an open letter to company executives and chairpersons setting out how COVID 19 has changed its engagement priorities and how the pandemic should change global businesses for the better.

Hans-Christoph Hirt, head of Equity Ownership Services at Federated Hermes, which advises on more than $875 billion in assets, said the crisis had reinforced his firm’s belief that companies needed “a social licence” to operate.

Hirt called on executives to ensure the safety and wellbeing of their workforces, to treat suppliers fairly and support the efforts of governments in dealing with COVID-19.

He also said companies needed to be better prepared for rapid crisis responses in the future.

“Business and governments will need to learn from and comprehensively act on the lessons from this crisis, not only for future pandemics, but for other known risks, such as the climate crisis – an emergency that requires far greater planning, resolve and commitment than we have seen so far in addressing the Coronavirus pandemic in most countries.”

The investor has also modified voting policies for the 2020 shareholder meeting season, allowing greater flexibility on the re-election of some board members to avoid any unnecessary disruption to company management at this time.

It also said it would support companies that are “prudent” as they navigate the impact of the pandemic, particularly when it comes to strengthening balance sheets and mothballing dividends.

Reporting By Sinead Cruise, editing by Carolyn Cohn and Simon Jessop

Source Article

Next Post

Coronavirus vaccine race 'is a global effort' for mankind, Germany's vaccine expert says

Dr. Sonia Macieiewski (R) and Dr. Nita Patel, Director of Antibody discovery and Vaccine development, look at a sample of a respiratory virus at Novavax labs in Rockville, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19. Andrew Caballero-Reynolds | AFP | Getty […]